Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-03-25
2008-03-25
Maier, Leigh C. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S356000, C514S398000
Reexamination Certificate
active
07348317
ABSTRACT:
An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.75%. The solution contains a combination of solubility-enhancing agents, one of which is a cyclodextrin such as beta-cyclodextrin and the second is niacin or niacinamide. Methods of manufacture and therapeutic use of the solution are disclosed.
REFERENCES:
patent: 4032645 (1977-06-01), Chien et al.
patent: 4267169 (1981-05-01), Kamishita et al.
patent: 4596795 (1986-06-01), Pitha
patent: 4727064 (1988-02-01), Pitha
patent: 4837378 (1989-06-01), Borgman
patent: 5324718 (1994-06-01), Loftsson
patent: 5472954 (1995-12-01), Loftsson
patent: 5536743 (1996-07-01), Borgman
patent: 5646131 (1997-07-01), Badwan
patent: 5747341 (1998-05-01), Brothers
patent: 5849776 (1998-12-01), Czernielewski et al.
patent: 5928942 (1999-07-01), Brothers
patent: 6183766 (2001-02-01), Sine et al.
patent: 6468989 (2002-10-01), Chang et al.
patent: 0 149 197 (1990-03-01), None
patent: 0 472 327 (1991-08-01), None
patent: 0 335 545 (1993-06-01), None
patent: WO 85/02767 (1985-07-01), None
patent: WO 90/03784 (1990-04-01), None
patent: WO 91/11172 (1991-08-01), None
patent: WO 94/02518 (1994-02-01), None
patent: WO 99/09988 (1999-03-01), None
Pederson, M. “Effect of hydrotropic substances on the complexation . . . ” Drug Dev. Ind. Pharm. (1993) vol. 19, No. 4, pp. 439-448.
Uekama, K, and Otagiri, M, Cyclodextrins In Drug Carrier Systems, CRC Critical Review In Therapeutic Drug Carrier Systems, vol. 3(1):1-40 (1987).
Chien, YW, Solubilization of Metronidazole by Water-miscible Multi-cosolvents and Water-soluble Vitamins, Journal of Parenteral Science and Technology, vol. 38(1):32-36 (1984).
Giordano, F., et al., Preparation and Characterization of Metronidazole Benzoate-Gammacyclodextrin Inclusion Compound, Boll. Chim. Farmaceutico, vol. 131(4):150-156 (1992).
Andersen, FM, and Bundgaard, H, Inclusion complexation of metronidazole benzoate with β-cyclodextrin and its depression of anhydrate-hydrate transition in aqueous suspensions, International Journal of Pharmaceutics, vol. 19:189-197 (1984).
Skiba, M., et al., Development of a new colloidal drug carrier from chemically-modified cyclodexrins: nanospheres and Influence of physicochemical and technological factors on particle size, International Journal of Pharmaceutics, vol. 129:113-121 (1996).
Kata, M., and Kedvessy, G., Increasing the solubility characteristics of Pharmacs with cyclodextrins, Pharm. Ind., vol. 49:98-100 (1997).
Kata, M., and Antal, A., Production and Investigation of products containing metronidazole and β-cyclodextrin, Acta Pharmaceutica Hungarica, 54:116-122 (1984).
Hadi, IA al, Formulation factors and physical properties of metronidazole benzoate tablets containing mixtures of β-cyclodextrins and its derivatives, Congr. Int. Tech. Pharm., 6th, 5:401-407 (1992).
European Pharmacopoeia, pp. 980-981 (1995).
Physicians Desk Reference, 53 Edition, pp. 912-913 (1999).
Szejtli, J.,Cyclodextrins in Drug Formulations: Part 1, Pharmaceutical Technology International, vol. 3(2):15-22 (1991).
Szejtli, J.,Cyclodextrins in Drug Formulations: Part 2Pharmaceutical Technology International, vol. 3(3):16-24 (1991).
Lofftson et al.,2-Hydroxypropyl-β-cyclodextrin: Properties and Usage in Pharmaceautical Formulations, Pharm. Ztg. Wiss., vol. 4/13:5-10 (1991).
Hirayama et al., inCyclodextrins and their Industrial Uses, ed. D. Duchene, Editions de Sante, Paris, 1987, pp. 133-172.
Hassan et al.,Improvement of the in vitro dissolution characteristics of famotidine by inclusion in β-cyclodextrin, International Journal of Pharmaceutics, 58:19-24 (1990).
Loftsson, T., and Bodor, N.,Effects of 2-hydroxypropyl-β-cyclodextrin on the aqueous solubility of drugs and transderman delivery of 17β-estradiol, Acta. Pharm. Nord., 1(4):186-193 (1989).
Pagington, J.S.,β-Cyclodextrin: the success of molecular inclusion, Chemistry in Britain, pp. 455-458 (May 1987).
Loftsson, T., et al.,the effects of cyclodextrin on transdermal delivery of drugs, European J. Pharm. Biopharm., 37(1):30-33 (1991).
Redenti, E, et al, Drug/Cyclodextrin/Hydroxy Acid Multicomponent Systems. Properties and Pharmaceutical Applications, J. Pharmaceutical Sciences, 89 (1): 1-8 (2000).
Chang Yunik
Dow Gordon J.
Dow Pharmaceutical Sciences
Eisenberg, Esq. Howard
Maier Leigh C.
LandOfFree
Aqueous compositions containing metronidazole does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aqueous compositions containing metronidazole, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aqueous compositions containing metronidazole will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2807597